Literature DB >> 8439954

Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1.

Z Pietrzkowski1, G Mulholland, L Gomella, B A Jameson, D Wernicke, R Baserga.   

Abstract

We have investigated three prostatic cancer cell lines, PC-3, DU-145, and LNCa.FGC, and found that all three cell lines can grow in serum-free medium without the addition of exogenous growth factors. All three cell lines produce substantial amounts of insulin-like growth factor 1 (IGF-1) that is secreted in the medium and they all display constitutively autophosphorylated IGF-1 receptors; two of the cell lines overexpress IGF-1 receptor RNA. The growth of all three cell lines is inhibited by an antisense oligodeoxynucleotide to IGF-1 receptor RNA or by peptide analogues of IGF-1 that compete with IGF-1 binding to its receptor. Our results indicate that these three cell lines grow by an autocrine loop in which the overproduced IGF-1 activates its receptor. Interference with the activation of the receptor leads to cessation of growth.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8439954

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo.

Authors:  P Burfeind; C L Chernicky; F Rininsland; J Ilan; J Ilan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Inhibition of IGF-1R diminishes transcriptional activity of the androgen receptor and its constitutively active, C-terminally truncated counterparts Q640X and AR-V7.

Authors:  Friedemann Zengerling; Anca Azoitei; Alexander Herweg; Florian Jentzmik; Marcus V Cronauer
Journal:  World J Urol       Date:  2015-08-29       Impact factor: 4.226

3.  Enterolactone inhibits insulin-like growth factor-1 receptor signaling in human prostatic carcinoma PC-3 cells.

Authors:  Li-Hua Chen; Jing Fang; Zhijian Sun; Huaixing Li; Ying Wu; Wendy Demark-Wahnefried; Xu Lin
Journal:  J Nutr       Date:  2009-02-11       Impact factor: 4.798

Review 4.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

5.  A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians.

Authors:  Fredrick R Schumacher; Iona Cheng; Matthew L Freedman; Lorelei Mucci; Naomi E Allen; Michael N Pollak; Richard B Hayes; Daniel O Stram; Federico Canzian; Brian E Henderson; David J Hunter; Jarmo Virtamo; Jonas Manjer; J Michael Gaziano; Laurence N Kolonel; Anne Tjønneland; Demetrius Albanes; Eugenia E Calle; Edward Giovannucci; E David Crawford; Christopher A Haiman; Peter Kraft; Walter C Willett; Michael J Thun; Loïc Le Marchand; Rudolf Kaaks; Heather Spencer Feigelson; H Bas Bueno-de-Mesquita; Domenico Palli; Elio Riboli; Eiliv Lund; Pilar Amiano; Gerald Andriole; Alison M Dunning; Dimitrios Trichopoulos; Meir J Stampfer; Timothy J Key; Jing Ma
Journal:  Hum Mol Genet       Date:  2010-05-19       Impact factor: 6.150

6.  In vitro and in vivo model systems used in prostate cancer research.

Authors:  David Cunningham; Zongbing You
Journal:  J Biol Methods       Date:  2015

7.  Consumption of dairy and meat in relation to breast cancer risk in the Black Women's Health Study.

Authors:  Jeanine M Genkinger; Kepher H Makambi; Julie R Palmer; Lynn Rosenberg; Lucile L Adams-Campbell
Journal:  Cancer Causes Control       Date:  2013-01-18       Impact factor: 2.506

8.  Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts.

Authors:  C Sell; G Dumenil; C Deveaud; M Miura; D Coppola; T DeAngelis; R Rubin; A Efstratiadis; R Baserga
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

Review 9.  Prostate cancer progression. Implications of histopathology.

Authors:  J L Ware
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

Review 10.  Endothelin-1 as a target for therapeutic intervention in prostate cancer.

Authors:  E Scott Kopetz; Joel B Nelson; Michael A Carducci
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.